Human stem cell-derived β cells expressing an optimized CD155 reduce cytotoxic immune cell function for application in type 1 diabetes
Science Advances · 2025
DOI: 10.1126/sciadv.adx9755 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Advances, 2025. Verfasst von Matthew E Brown und 5 weiteren Autor:innen. Beteiligte Einrichtung: Diabetes Institute, University of Florida, Gainesville, FL, USA. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 1, Insulin-Secreting Cells, Receptors, Virus, Cytotoxicity, Immunologic. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, NIDDK NIH HHS.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Insulin-producing β cell replacement therapies show promise for treating type 1 diabetes (T1D), but challenges such as donor shortages and immune rejection persist. Stem cell–derived β cells (sBC) provide a renewable source but remain susceptible to immune attack. We engineered human pluripotent stem cells to express either the wild type (WT) or a high-affinity mutant (Mut) variant (rs1058402, G>A; Ala 67 Thr) of the natural killer (NK) and T cell checkpoint inhibitor CD155 before differentiation into sBC. Modified sBC maintained up-regulated CD155 expression and showed enhanced binding to co-receptor ligands. Co-culture studies revealed CD155-expressing sBC suppressed autoreactive CD8 + T cell and NK cell activation, reducing immune cell–mediated sBC destruction and cytotoxic molecule secretion by preferentially engaging the coinhibitory receptor TIGIT. This protection was lost with TIGIT blockade, affirming the role of CD155-TIGIT signaling in antagonizing immune cell cytotoxicity. Our findings suggest that high-affinity CD155 expression enhances immune evasion of sBC, improving their potential as a therapy for T1D.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Diabetes Institute, University of Florida, Gainesville, FL, USA.
- Department of Pathology, Immunology and Laboratory Medicine, College of Medicine, University of Florida, Gainesville, FL, USA.
- Department of Pharmacology and Therapeutics, College of Medicine, University of Florida, Gainesville, FL, USA.
- Department of Pediatrics, College of Medicine, University of Florida, Gainesville, FL, USA.
- Department of Biochemistry and Molecular Biology, College of Medicine, University of Florida, Gainesville, FL, USA.
ORCID-Profile: Matthew E Brown, Jessie M Barra, Marcus R Pina, James Proia, Todd M Brusko, Holger A Russ
Förderung
- NIAID NIH HHS
- NIDDK NIH HHS
Zitieren
APA
Brown, M. E., Barra, J. M., Pina, M. R., Proia, J., Brusko, T. M., & Russ, H. A. (2025). Human stem cell-derived β cells expressing an optimized CD155 reduce cytotoxic immune cell function for application in type 1 diabetes. Science Advances. https://doi.org/10.1126/sciadv.adx9755
Vancouver
Brown ME, Barra JM, Pina MR, Proia J, Brusko TM, Russ HA. Human stem cell-derived β cells expressing an optimized CD155 reduce cytotoxic immune cell function for application in type 1 diabetes. Science Advances. 2025. doi:10.1126/sciadv.adx9755
BibTeX
@article{Brown2025,
author = {Brown, Matthew E and Barra, Jessie M and Pina, Marcus R and Proia, James and Brusko, Todd M and Russ, Holger A},
title = {Human stem cell-derived β cells expressing an optimized CD155 reduce cytotoxic immune cell function for application in type 1 diabetes},
journal = {Science Advances},
year = {2025},
doi = {10.1126/sciadv.adx9755}
}
EUVIMED